Sudipta Hazra

Antileishmanial lead structures from nature: analysis of structure-activity relationships of a compound library derived from caffeic Acid bornyl ester.

Bioassay-guided fractionation of a chloroform extract of Valeriana wallichii (V. wallichii) rhizomes lead to the isolation and identification of caffeic acid bornyl ester (1) as the active component against Leishmania major (L. major) promastigotes (IC50 = 48.8 µM). To investigate the structure-activity relationship (SAR), a library of compounds based on 1 was synthesized and tested in vitro against L. major and L. donovani promastigotes, and L. major amastigotes. Cytotoxicity was determined using a murine J774.1 cell line and bone marrow derived macrophages (BMDM). Some compounds showed antileishmanial activity in the concentration range of pentamidine and miltefosine which are the standard drugs in use. In the L. major amastigote assay compounds 15, 19 and 20 showed good activity with relatively low cytotoxicity against BMDM, resulting in acceptable selectivity indices. Molecules with adjacent phenolic hydroxyl groups exhibited elevated cytotoxicity against murine cell lines J774.1 and BMDM. The Michael system seems not to be essential for antileishmanial activity. Based on the results compound 27 can be regarded as new lead structure for further structure optimization.

Evaluation of a diospyrin derivative as antileishmanial agent and potential modulator of ornithine decarboxylase of Leishmania donovani

World health organization has called for academic research and development of new chemotherapeutic strategies to overcome the emerging resistance and side effects exhibited by the drugs currently used against leishmaniasis. Diospyrin, a bis-naphthoquinone isolated from Diospyros montana Roxb., and its semi-synthetic derivatives, were reported for inhibitory activity against protozoan parasites including Leishmania. Presently, we have investigated the antileishmanial effect of a di-epoxide derivative of diospyrin (D17), both in vitro and in vivo. Further, the safety profile of D17 was established by testing its toxicity against normal macrophage cells (IC₅₀∼20.7 μM), and also against normal BALB/c mice in vivo. The compound showed enhanced activity (IC₅₀∼7.2 μM) as compared to diospyrin (IC₅₀∼12.6 μM) against Leishmania donovani promastigotes. Again, D17 was tested on L. donovani BHU1216 isolated from a sodium stibogluconate-unresponsive patient, and exhibited selective inhibition of the intracellular amastigotes (IC₅₀∼0.18 μM). Also, treatment of infected BALB/c mice with D17 at 2mg/kg/day reduced the hepatic parasite load by about 38%. Subsequently, computational docking studies were undertaken on selected enzymes of trypanothione metabolism, viz. trypanothione reductase (TryR) and ornithine decarboxylase (ODC), followed by the enzyme kinetics, where D17 demonstrated non-competitive inhibition of the L. donovani ODC, but could not inhibit TryR.

Cinnamic Acid Bornyl Ester Derivatives from Valeriana wallichii Exhibit Antileishmanial In Vivo Activity in Leishmania major-Infected BALB/c Mice

Human leishmaniasis covers a broad spectrum of clinical manifestations ranging from self-healing cutaneous leishmaniasis to severe and lethal visceral leishmaniasis caused among other species by Leishmania major or Leishmania donovani, respectively. Some drug candidates are in clinical trials to substitute current therapies, which are facing emerging drug-resistance accompanied with serious side effects. Here, two cinnamic acid bornyl ester derivatives (1 and 2) were assessed for their antileishmanial activity. Good selectivity and antileishmanial activity of bornyl 3-phenylpropanoate (2) in vitro prompted the antileishmanial assessment in vivo. For this purpose, BALB/c mice were infected with Leishmania major promastigotes and treated with three doses of 50 mg/kg/day of compound 2. The treatment prevented the characteristic swelling at the site of infection and correlated with reduced parasite burden. Transmitted light microscopy and transmission electron microscopy of Leishmania major promastigotes revealed that compounds 1 and 2 induce mitochondrial swelling. Subsequent studies on Leishmania major promastigotes showed the loss of mitochondrial transmembrane potential (ΔΨm) as a putative mode of action. As the cinnamic acid bornyl ester derivatives 1 and 2 had exhibited antileishmanial activity in vitro, and compound 2 in Leishmania major-infected BALB/c mice in vivo, they can be regarded as possible lead structures for the development of new antileishmanial therapeutic approaches.

Phytochemicals With Antileishmanial Activity: Prospective Drug Targets

Abstract Protozoan parasites are among the most common causative agents of some of the major tropical diseases occurring in both humans and domestic animals, leading to enormous loss of life and productivity. Leishmaniases are classified as “neglected tropical diseases” with a huge global burden of vector-borne diseases caused by parasites belonging to the genus Leishmania . Typically manifested in visceral, cutaneous, and mucocutaneous forms, leishmaniasis is endemic in some regions of Asia, Africa, and South America. Visceral leishmaniasis (VL) is the most severe clinical appearance of this ailment, known as kala-azar in the Indian subcontinent. Characterized by its effect on the internal organs—particularly the liver, spleen, and bone marrow—VL is often associated with marked suppression of the hosts cell-mediated immune response, leading to severe morbidity, even mortality, if left untreated. The management of leishmaniasis depends solely on a limited range of drugs, since a vaccine to combat the disease is not available till date. Pentavalent antimonials are the oldest and foremost line of therapeutics, despite shortcomings like prolonged intravenous regimen, lack of efficacy, and side effects. The other alternatives like pentamidine and amphotericin B also suffer from the limitation of toxicity, while the liposomal formulation of the latter is too expensive. The situation is further aggravated due to the growing unresponsiveness of VL to the antimonials. Even miltefosine, the only oral formulation of an anticancer agent introduced for the treatment of kala-azar in India, has also indicated potential resistance, including concerns about the eventuality of teratogenicity. Thus, it is an ongoing challenge to discover new drugs for the treatment of leishmaniasis. Identification of a molecular target is an important step in drug development against any particular disease. It is expected that the plant kingdom would provide valuable “leads” that could be explored in order to design novel therapeutic agents specifically active against leishmania parasites. A glimpse of the recent findings on prospective compounds, their mechanism of action, and development of potent analogues based on the natural templates will be presented in this chapter.